A detailed history of Price T Rowe Associates Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,980,249 shares of MLTX stock, worth $157 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,980,249
Previous 2,561,512 16.35%
Holding current value
$157 Million
Previous $113 Million 33.41%
% of portfolio
0.02%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.15 - $55.4 $16.8 Million - $23.2 Million
418,737 Added 16.35%
2,980,249 $150 Million
Q2 2024

Aug 14, 2024

BUY
$38.43 - $48.6 $16.4 Million - $20.7 Million
425,629 Added 19.93%
2,561,512 $113 Million
Q1 2024

May 15, 2024

SELL
$43.78 - $63.86 $7.8 Million - $11.4 Million
-178,129 Reduced 7.7%
2,135,883 $107 Million
Q4 2023

Feb 14, 2024

BUY
$36.35 - $63.02 $7.13 Million - $12.4 Million
196,144 Added 9.26%
2,314,012 $140 Million
Q3 2023

Nov 14, 2023

BUY
$48.35 - $61.26 $8.45 Million - $10.7 Million
174,812 Added 9.0%
2,117,868 $121 Million
Q2 2023

Aug 14, 2023

BUY
$19.01 - $51.79 $21.1 Million - $57.6 Million
1,112,150 Added 133.85%
1,943,056 $99.1 Million
Q1 2023

May 15, 2023

BUY
$11.03 - $23.7 $91,604 - $196,828
8,305 Added 1.01%
830,906 $17.8 Million
Q4 2022

Feb 14, 2023

SELL
$7.05 - $10.5 $329,848 - $491,263
-46,787 Reduced 5.38%
822,601 $8.64 Million
Q3 2022

Nov 14, 2022

SELL
$5.25 - $9.27 $5,964 - $10,530
-1,136 Reduced 0.13%
869,388 $6.92 Million
Q2 2022

Aug 15, 2022

BUY
$4.69 - $13.25 $4.08 Million - $11.5 Million
870,524 New
870,524 $4.44 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.94B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.